Advertisement

Boosting Muscle Regeneration

  • Tommaso Nastasi
  • Nadia Rosenthal
Chapter
  • 2.5k Downloads
Part of the Advances in Muscle Research book series (ADMR, volume 3)

Keywords

Amyotrophic Lateral Sclerosis Satellite Cell Muscle Atrophy Skeletal Muscle Mass Muscle Wasting 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Agrawal S, Thakur P, Katoch SS (2003) Beta adrenoceptor agonists, clenbuterol, and isoproterenol retard denervation atrophy in rat gastrocnemius muscle: use of 3-methylhistidine as a marker of myofibrillar degeneration. Jpn J Physiol 53:229–237PubMedGoogle Scholar
  2. Allen DL, Leinwand LA (2001) Postnatal myosin heavy chain isoform expression in normal mice and mice null for IIb or IId myosin heavy chains. Dev Biol 229:383–395PubMedGoogle Scholar
  3. Arai C, Ohnuki Y, Umeki D, Hirashita A, Saeki Y (2006) Effects of clenbuterol and cyclosporin A on the myosin heavy chain mRNA level and the muscle mass in rat masseter. J Physiol Sci 56:205–209PubMedGoogle Scholar
  4. Attaix D, Ventadour S, Codran A, Bechet D, Taillandier D, Combaret L (2005) The ubiquitin-proteasome system and skeletal muscle wasting. Essays Biochem 41:173–186PubMedGoogle Scholar
  5. Bahrke MS, Yesalis CE (2004) Abuse of anabolic androgenic steroids and related substances in sport and exercise. Curr Opin Pharmacol 4:614–620PubMedGoogle Scholar
  6. Barton ER (2006) Viral expression of insulin-like growth factor-I isoforms promotes different responses in skeletal muscle. J Appl Physiol 100:1778–1784PubMedGoogle Scholar
  7. Barton ER, Morris L, Musaro A, Rosenthal N, Sweeney HL (2002) Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J Cell Biol 157:137–148PubMedGoogle Scholar
  8. Bassel-Duby R, Olson EN (2003) Role of calcineurin in striated muscle: development, adaptation, and disease. Biochem Biophys Res Commun 311:1133–1141PubMedGoogle Scholar
  9. Bassel-Duby R, Olson EN (2006) Signaling pathways in skeletal muscle remodeling. Annu Rev Biochem 75:19–37PubMedGoogle Scholar
  10. Bodine SC (2006) mTOR Signaling and the Molecular Adaptation to Resistance Exercise. Med Sci Sports Exerc 38:1950–1957PubMedGoogle Scholar
  11. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K, Pan ZQ, Valenzuela DM, DeChiara TM, Stitt TN, Yancopoulos GD, Glass DJ (2001a) Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294:1704–1708Google Scholar
  12. Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Bauerlein R, Zlotchenko E, Scrimgeour A, Lawrence JC, Glass DJ, Yancopoulos GD (2001b) Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol 3:1014–1019Google Scholar
  13. Bogdanovich S, Perkins KJ, Krag TO, Whittemore LA, Khurana TS (2005) Myostatin propeptide-mediated amelioration of dystrophic pathophysiology. Faseb J 19:543–549PubMedGoogle Scholar
  14. Bonizzi G, Karin M (2004) The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25:280–288PubMedGoogle Scholar
  15. Buckingham M (2003) How the community effect orchestrates muscle differentiation. Bioessays 25:13–16PubMedGoogle Scholar
  16. Buckingham M (2006) Myogenic progenitor cells and skeletal myogenesis in vertebrates. Curr Opin Genet Dev 16:525–532PubMedGoogle Scholar
  17. Buckingham M, Bajard L, Chang T, Daubas P, Hadchouel J, Meilhac S, Montarras D, Rocancourt D, Relaix F (2003) The formation of skeletal muscle: from somite to limb. J Anat 202:59–68PubMedGoogle Scholar
  18. Burdi R, Didonna MP, Pignol B, Nico B, Mangieri D, Rolland JF, Camerino C, Zallone A, Ferro P, Andreetta F, Confalonieri P, De Luca A (2006) First evaluation of the potential effectiveness in muscular dystrophy of a novel chimeric compound, BN 82270, acting as calpain-inhibitor and anti-oxidant. Neuromuscul Disord 16:237–248PubMedGoogle Scholar
  19. Burkard N, Becher J, Heindl C, Neyses L, Schuh K, Ritter O (2005) Targeted proteolysis sustains calcineurin activation. Circulation 111:1045–1053PubMedGoogle Scholar
  20. Burniston JG, Clark WA, Tan LB, Goldspink DF (2006) Dose-dependent separation of the hypertrophic and myotoxic effects of the beta(2)-adrenergic receptor agonist clenbuterol in rat striated muscles. Muscle Nerve 33:655–663PubMedGoogle Scholar
  21. Burniston JG, McLean L, Beynon RJ, Goldspink DF (2007) Anabolic effects of a non-myotoxic dose of the beta2-adrenergic receptor agonist clenbuterol on rat plantaris muscle. Muscle Nerve 35:217–223PubMedGoogle Scholar
  22. Burniston JG, Ng Y, Clark WA, Colyer J, Tan LB, Goldspink DF (2002) Myotoxic effects of clenbuterol in the rat heart and soleus muscle. J Appl Physiol 93:1824–1832PubMedGoogle Scholar
  23. Cai D, Frantz JD, Tawa NE, Jr., Melendez PA, Oh BC, Lidov HG, Hasselgren PO, Frontera WR, Lee J, Glass DJ, Shoelson SE (2004) IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 119:285–298PubMedGoogle Scholar
  24. Cao PR, Kim HJ, Lecker SH (2005) Ubiquitin-protein ligases in muscle wasting. Int J Biochem Cell Biol 37:2088–2097PubMedGoogle Scholar
  25. Carlson CJ, Booth FW, Gordon SE (1999) Skeletal muscle myostatin mRNA expression is fiber-type specific and increases during hindlimb unloading. Am J Physiol 277:R601–R606PubMedGoogle Scholar
  26. Chakkalakal JV, Thompson J, Parks RJ, Jasmin BJ (2005) Molecular, cellular, and pharmacological therapies for Duchenne/Becker muscular dystrophies. Faseb J 19:880–891PubMedGoogle Scholar
  27. Chen YG, Meng AM (2004) Negative regulation of TGF-beta signaling in development. Cell Res 14:441–449PubMedGoogle Scholar
  28. Chien KR, Karsenty G (2005) Longevity and lineages: toward the integrative biology of degenerative diseases in heart, muscle, and bone. Cell 120:533–544PubMedGoogle Scholar
  29. Cho H, Thorvaldsen JL, Chu Q, Feng F, Birnbaum MJ (2001) Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem 276:38349–38352PubMedGoogle Scholar
  30. Christ B, Brand-Saberi B (2002) Limb muscle development. Int J Dev Biol 46:905–914PubMedGoogle Scholar
  31. Ciechanover A (2005) Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Cell Death Differ 12:1178–1190PubMedGoogle Scholar
  32. Close GL, Kayani A, Vasilaki A, McArdle A (2005) Skeletal muscle damage with exercise and aging. Sports Med 35:413–427PubMedGoogle Scholar
  33. Cossu G, Biressi S (2005) Satellite cells, myoblasts and other occasional myogenic progenitors: possible origin, phenotypic features and role in muscle regeneration. Semin Cell Dev Biol 16:623–631PubMedGoogle Scholar
  34. Dasarathy S, Dodig M, Muc SM, Kalhan SC, McCullough AJ (2004) Skeletal muscle atrophy is associated with an increased expression of myostatin and impaired satellite cell function in the portacaval anastamosis rat. Am J Physiol Gastrointest Liver Physiol 287:G1124–G1130PubMedGoogle Scholar
  35. Dehoux M, Gobier C, Lause P, Bertrand L, Ketelslegers JM, Thissen JP (2007) IGF-I does not prevent myotube atrophy caused by proinflammatory cytokines despite activation of Akt/Foxo and GSK3β pathways and inhibition of Atrogin-1 mRNA. Am J Physiol Endocrinol Metab 292:E145–E150PubMedGoogle Scholar
  36. Delafontaine P, Akao M (2006) Angiotensin II as candidate of cardiac cachexia. Curr Opin Clin Nutr Metab Care 9:220–224PubMedGoogle Scholar
  37. Dobrowolny G, Giacinti C, Pelosi L, Nicoletti C, Winn N, Barberi L, Molinaro M, Rosenthal N, Musaro A (2005) Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model. J Cell Biol 168:193–199PubMedGoogle Scholar
  38. Dodd SL, Koesterer TJ (2002) Clenbuterol attenuates muscle atrophy and dysfunction in hindlimb-suspended rats. Aviat Space Environ Med 73:635–639PubMedGoogle Scholar
  39. Duguez S, Bartoli M, Richard I (2006) Calpain 3: a key regulator of the sarcomere? Febs J 273:3427–3436PubMedGoogle Scholar
  40. Edstrom E, Ulfhake B (2005) Sarcopenia is not due to lack of regenerative drive in senescent skeletal muscle. Aging Cell 4:65–77PubMedGoogle Scholar
  41. Eizema K, van der Wal DE, van den Burg MM, de Jonge HW, Everts ME (2007) Differential Expression of Calcineurin and SR Ca2+ Handling Proteins in Equine Muscle Fibers During Early Postnatal Growth. J Histochem Cytochem 55:247–254Google Scholar
  42. Etherton TD (2004) Somatotropic function: the somatomedin hypothesis revisited. J Anim Sci 82 E-Suppl:E239–E244PubMedGoogle Scholar
  43. Fareed MU, Evenson AR, Wei W, Menconi M, Poylin V, Petkova V, Pignol B, Hasselgren PO (2006) Treatment of rats with calpain inhibitors prevents sepsis-induced muscle proteolysis independent of atrogin-1/MAFbx and MuRF1 expression. Am J Physiol Regul Integr Comp Physiol 290:R1589–1597PubMedGoogle Scholar
  44. Fogarty MP, Kessler JD, Wechsler-Reya RJ (2005) Morphing into cancer: the role of developmental signaling pathways in brain tumor formation. J Neurobiol 64:458–475PubMedGoogle Scholar
  45. Friday BB, Horsley V, Pavlath GK (2000) Calcineurin activity is required for the initiation of skeletal muscle differentiation. J Cell Biol 149:657–666PubMedGoogle Scholar
  46. Geiger PC, Bailey JP, Mantilla CB, Zhan WZ, Sieck GC (2006) Mechanisms underlying myosin heavy chain expression during development of the rat diaphragm muscle. J Appl Physiol 101:1546–1555PubMedGoogle Scholar
  47. Ghosh S, Karin M (2002) Missing pieces in the NF-kappaB puzzle. Cell 109 Suppl:S81–S96PubMedGoogle Scholar
  48. Gilson H, Schakman O, Combaret L, Lause P, Grobet L, Attaix D, Ketelslegers JM, Thissen JP (2007) Myostatin Gene Deletion Prevents Glucocorticoid-Induced Muscle Atrophy. Endocrinology 148:452–460PubMedGoogle Scholar
  49. Glass DJ (2005) Skeletal muscle hypertrophy and atrophy signaling pathways. Int J Biochem Cell Biol 37:1974–1984PubMedGoogle Scholar
  50. Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL (2001) Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci U S A 98:14440–14445PubMedGoogle Scholar
  51. Gonzalez-Cadavid NF, Taylor WE, Yarasheski K, Sinha-Hikim I, Ma K, Ezzat S, Shen R, Lalani R, Asa S, Mamita M, Nair G, Arver S, Bhasin S (1998) Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Proc Natl Acad Sci U S A 95:14938–14943PubMedGoogle Scholar
  52. Guttridge DC (2004) Signaling pathways weigh in on decisions to make or break skeletal muscle. Curr Opin Clin Nutr Metab Care 7:443–450PubMedGoogle Scholar
  53. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr (1999) NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 19:5785–5799PubMedGoogle Scholar
  54. Guttridge DC, Mayo MW, Madrid LV, Wang CY, Baldwin AS Jr (2000) NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 289:2363–2366PubMedGoogle Scholar
  55. Haisma HJ, de Hon O (2006) Gene doping. Int J Sports Med 27:257–266Google Scholar
  56. Harridge SD (2003) Ageing and local growth factors in muscle. Scand J Med Sci Sports 13:34–39PubMedGoogle Scholar
  57. Hartgens F, Kuipers H (2004) Effects of androgenic-anabolic steroids in athletes. Sports Med 34:513–554PubMedGoogle Scholar
  58. Heineke J, Molkentin JD (2006) Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 7:589–600PubMedGoogle Scholar
  59. Herbst KL, Bhasin S (2004) Testosterone action on skeletal muscle. Curr Opin Clin Nutr Metab Care 7:271–277PubMedGoogle Scholar
  60. Hesselink MK, van Baak MA (2004) Physical activity and health, novel concepts and new targets: report from the 12th Conference of the International Research Group on the Biochemistry of Exercise. Proc Nutr Soc 63:189–197PubMedGoogle Scholar
  61. Hollway GE, Currie PD (2003) Myotome meanderings. Cellular morphogenesis and the making of muscle. EMBO Rep 4:855–860PubMedGoogle Scholar
  62. Holzbaur EL, Howland DS, Weber N, Wallace K, She Y, Kwak S, Tchistiakova LA, Murphy E, Hinson J, Karim R, Tan XY, Kelley P, McGill KC, Williams G, Hobbs C, Doherty P, Zaleska MM, Pangalos MN, Walsh FS (2006) Myostatin inhibition slows muscle atrophy in rodent models of amyotrophic lateral sclerosis. Neurobiol Dis 23:697–707PubMedGoogle Scholar
  63. Horsley V, Friday BB, Matteson S, Kegley KM, Gephart J, Pavlath GK (2001) Regulation of the growth of multinucleated muscle cells by an NFATC2-dependent pathway. J Cell Biol 153:329–338PubMedGoogle Scholar
  64. Horsley V, Jansen KM, Mills ST, Pavlath GK (2003) IL-4 acts as a myoblast recruitment factor during mammalian muscle growth. Cell 113:483–494PubMedGoogle Scholar
  65. Hubmacher D, Tiedemann K, Reinhardt DP (2006) Fibrillins: from biogenesis of microfibrils to signaling functions. Curr Top Dev Biol 75:93–123PubMedGoogle Scholar
  66. Izzi L, Attisano L (2006) Ubiquitin-dependent regulation of TGFbeta signaling in cancer. Neoplasia 8:677–688PubMedGoogle Scholar
  67. Jagoe RT, Goldberg AL (2001) What do we really know about the ubiquitin-proteasome pathway in muscle atrophy? Curr Opin Clin Nutr Metab Care 4:183–190PubMedGoogle Scholar
  68. Jones SW, Hill RJ, Krasney PA, O’Conner B, Peirce N, Greenhaff PL (2004) Disuse atrophy and exercise rehabilitation in humans profoundly affects the expression of genes associated with the regulation of skeletal muscle mass. Faseb J 18:1025–1027PubMedGoogle Scholar
  69. Joulia D, Bernardi H, Garandel V, Rabenoelina F, Vernus B, Cabello G (2003) Mechanisms involved in the inhibition of myoblast proliferation and differentiation by myostatin. Exp Cell Res 286:263–275PubMedGoogle Scholar
  70. Joulia-Ekaza D, Cabello G (2006) Myostatin regulation of muscle development: molecular basis, natural mutations, physiopathological aspects. Exp Cell Res 312:2401–2414PubMedGoogle Scholar
  71. Kandarian SC, Jackman RW (2006) Intracellular signaling during skeletal muscle atrophy. Muscle Nerve 33:155–165PubMedGoogle Scholar
  72. Karakelides H, Sreekumaran Nair K (2005) Sarcopenia of aging and its metabolic impact. Curr Top Dev Biol 68:123–148PubMedGoogle Scholar
  73. Karin M, Yamamoto Y, Wang QM (2004) The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 3:17–26PubMedGoogle Scholar
  74. Kemp SF, Fowlkes JL, Thrailkill KM (2006) Efficacy and safety of mecasermin rinfabate. Expert Opin Biol Ther 6:533–538PubMedGoogle Scholar
  75. Kemp SF, Thrailkill KM (2006) Investigational agents for the treatment of growth hormone-insensitivity syndrome. Expert Opin Investig Drugs 15:409–415PubMedGoogle Scholar
  76. Kline WO, Panaro FJ, Yang H, Bodine SC (2007) Rapamycin Inhibits the Growth and Muscle Sparing Effects of Clenbuterol. J Appl Physiol 102:740–747PubMedGoogle Scholar
  77. Kluppel M, Wrana JL (2005) Turning it up a Notch: cross-talk between TGF beta and Notch signaling. Bioessays 27:115–118PubMedGoogle Scholar
  78. Kraemer WJ, Ratamess NA (2005) Hormonal responses and adaptations to resistance exercise and training. Sports Med 35:339–361PubMedGoogle Scholar
  79. Kramerova I, Beckmann JS, Spencer MJ (2007) Molecular and cellular basis of calpainopathy (limb girdle muscular dystrophy type 2A). Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1772:128–144Google Scholar
  80. Kramerova I, Kudryashova E, Venkatraman G, Spencer MJ (2005) Calpain 3 participates in sarcomere remodeling by acting upstream of the ubiquitin-proteasome pathway. Hum Mol Genet 14:2125–2134PubMedGoogle Scholar
  81. Kramerova I, Kudryashova E, Wu B, Spencer MJ (2006) Regulation of the M-Cadherin-β-Catenin Complex by Calpain 3 during Terminal Stages of Myogenic Differentiation. Mol Cell Biol 26:8437–8447PubMedGoogle Scholar
  82. Langen RC, Van Der Velden JL, Schols AM, Kelders MC, Wouters EF, Janssen-Heininger YM (2004) Tumor necrosis factor-alpha inhibits myogenic differentiation through MyoD protein destabilization. Faseb J 18:227–237PubMedGoogle Scholar
  83. Le Roith D, Bondy C, Yakar S, Liu JL, Butler A (2001a) The somatomedin hypothesis: 2001. Endocr Rev 22:53–74Google Scholar
  84. Le Roith D, Scavo L, Butler A (2001b) What is the role of circulating IGF-I? Trends Endocrinol Metab 12:48–52Google Scholar
  85. Lee SJ (2004) Regulation of muscle mass by myostatin. Annu Rev Cell Dev Biol 20:61–86PubMedGoogle Scholar
  86. Lee SJ, Reed LA, Davies MV, Girgenrath S, Goad ME, Tomkinson KN, Wright JF, Barker C, Ehrmantraut G, Holmstrom J, Trowell B, Gertz B, Jiang MS, Sebald SM, Matzuk M, Li E, Liang LF, Quattlebaum E, Stotish RL, Wolfman NM (2005) Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc Natl Acad Sci U S A 102:18117–18122PubMedGoogle Scholar
  87. Li Q, Verma IM (2002) NF-kB regulation in the immune system. Nat Rev Immunol 2:725–734PubMedGoogle Scholar
  88. Li YP (2003) TNF-alpha is a mitogen in skeletal muscle. Am J Physiol Cell Physiol 285:C370–C376PubMedGoogle Scholar
  89. Lin J, Arnold HB, Della-Fera MA, Azain MJ, Hartzell DL, Baile CA (2002) Myostatin knockout in mice increases myogenesis and decreases adipogenesis. Biochem Biophys Res Commun 291:701–706PubMedGoogle Scholar
  90. Luo D, Renault VM, Rando TA (2005) The regulation of Notch signaling in muscle stem cell activation and postnatal myogenesis. Semin Cell Dev Biol 16:612–622PubMedGoogle Scholar
  91. McCroskery S, Thomas M, Platt L, Hennebry A, Nishimura T, McLeay L, Sharma M, Kambadur R (2005) Improved muscle healing through enhanced regeneration and reduced fibrosis in myostatin-null mice. J Cell Sci 118:3531–3541PubMedGoogle Scholar
  92. McFarlane C, Plummer E, Thomas M, Hennebry A, Ashby M, Ling N, Smith H, Sharma M, Kambadur R (2006) Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-kappaB-independent, FoxO1-dependent mechanism. J Cell Physiol 209:501–514PubMedGoogle Scholar
  93. McLellan AS, Kealey T, Langlands K (2006) An E box in the exon 1 promoter regulates insulin-like growth factor-I expression in differentiating muscle cells. Am J Physiol Cell Physiol 291:C300–C307PubMedGoogle Scholar
  94. McMahon CD, Popovic L, Oldham JM, Jeanplong F, Smith HK, Kambadur R, Sharma M, Maxwell L, Bass JJ (2003) Myostatin-deficient mice lose more skeletal muscle mass than wild-type controls during hindlimb suspension. Am J Physiol Endocrinol Metab 285:E82–E87PubMedGoogle Scholar
  95. McManus EJ, Sakamoto K, Armit LJ, Ronaldson L, Shpiro N, Marquez R, Alessi DR (2005) Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis. Embo J 24:1571–1583PubMedGoogle Scholar
  96. McPherron AC, Lawler AM, Lee SJ (1997) Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387:83–90PubMedGoogle Scholar
  97. Miyazono K, Maeda S, Imamura T (2004) Coordinate regulation of cell growth and differentiation by TGF-beta superfamily and Runx proteins. Oncogene 23:4232–4237PubMedGoogle Scholar
  98. Morley JE, Thomas DR, Wilson MM (2006) Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 83:735–743PubMedGoogle Scholar
  99. Mourkioti F, Kratsios P, Luedde T, Song YH, Delafontaine P, Adami R, Parente V, Bottinelli R, Pasparakis M, Rosenthal N (2006) Targeted ablation of IKK2 improves skeletal muscle strength, maintains mass, and promotes regeneration. J Clin Invest 116:2945–2954PubMedGoogle Scholar
  100. Mourkioti F, Rosenthal N (2005) IGF-1, inflammation and stem cells: interactions during muscle regeneration. Trends Immunol 26:535–542PubMedGoogle Scholar
  101. Moustakas A, Heldin CH (2005) Non-Smad TGF-beta signals. J Cell Sci 118:3573–3584PubMedGoogle Scholar
  102. Musaro A, Giacinti C, Borsellino G, Dobrowolny G, Pelosi L, Cairns L, Ottolenghi S, Cossu G, Bernardi G, Battistini L, Molinaro M, Rosenthal N (2004) Stem cell-mediated muscle regeneration is enhanced by local isoform of insulin-like growth factor 1. Proc Natl Acad Sci U S A 101:1206–1210PubMedGoogle Scholar
  103. Musaro A, McCullagh K, Paul A, Houghton L, Dobrowolny G, Molinaro M, Barton ER, Sweeney HL, Rosenthal N (2001) Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet 27:195–200PubMedGoogle Scholar
  104. Musaro A, Rosenthal N (1999) Maturation of the myogenic program is induced by postmitotic expression of insulin-like growth factor I. Mol Cell Biol 19:3115–3124PubMedGoogle Scholar
  105. Muscaritoli M, Bossola M, Aversa Z, Bellantone R, Rossi Fanelli F (2006) Prevention and treatment of cancer cachexia: new insights into an old problem. Eur J Cancer 42:31–41PubMedGoogle Scholar
  106. Nader GA (2005) Molecular determinants of skeletal muscle mass: getting the “AKT” together. Int J Biochem Cell Biol 37:1985–1996PubMedGoogle Scholar
  107. Nastasi T, Bongiovanni A, Campos Y, Mann L, Toy JN, Bostrom J, Rottier R, Hahn C, Conaway JW, Harris AJ, D’Azzo A (2004) Ozz-E3, a muscle-specific ubiquitin ligase, regulates beta-catenin degradation during myogenesis. Dev Cell 6:269–282PubMedGoogle Scholar
  108. National Center for Health Statistics (2006) Health, United States, 2006. In: Hyatsville MD (ed) With Chartbook on Trends in the Helath of Americans, N. N. C. f. H. StatisticsGoogle Scholar
  109. Naya FJ, Mercer B, Shelton J, Richardson JA, Williams RS, Olson EN (2000) Stimulation of slow skeletal muscle fiber gene expression by calcineurin in vivo. J Biol Chem 275:4545–4548PubMedGoogle Scholar
  110. Noguchi S (2005) The biological function of insulin-like growth factor-I in myogenesis and its therapeutic effect on muscular dystrophy. Acta Myol 24:115–118PubMedGoogle Scholar
  111. Ohsawa Y, Hagiwara H, Nakatani M, Yasue A, Moriyama K, Murakami T, Tsuchida K, Noji S, Sunada Y (2006) Muscular atrophy of caveolin-3-deficient mice is rescued by myostatin inhibition. J Clin Invest 116:2924–2934PubMedGoogle Scholar
  112. Otani K, Polonsky KS, Holloszy JO, Han DH (2006) Inhibition of calpain results in impaired contraction-stimulated GLUT4 translocation in skeletal muscle. Am J Physiol Endocrinol Metab 291:E544–E548PubMedGoogle Scholar
  113. Parsons SA, Millay DP, Sargent MA, McNally EM, Molkentin JD (2006) Age-dependent effect of myostatin blockade on disease severity in a murine model of limb-girdle muscular dystrophy. Am J Pathol 168:1975–1985PubMedGoogle Scholar
  114. Parsons SA, Wilkins BJ, Bueno OF, Molkentin JD (2003) Altered skeletal muscle phenotypes in calcineurin Aalpha and Abeta gene-targeted mice. Mol Cell Biol 23:4331–4343PubMedGoogle Scholar
  115. Patel K, Macharia R, Amthor H (2005) Molecular mechanisms involving IGF-1 and myostatin to induce muscle hypertrophy as a therapeutic strategy for Duchenne muscular dystrophy. Acta Myol 24:230–241PubMedGoogle Scholar
  116. Paul AC, Rosenthal N (2002) Different modes of hypertrophy in skeletal muscle fibers. J Cell Biol 156:751–760PubMedGoogle Scholar
  117. Peng XD, Xu PZ, Chen ML, Hahn-Windgassen A, Skeen J, Jacobs J, Sundararajan D, Chen WS, Crawford SE, Coleman KG, Hay N (2003) Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev 17:1352–1365PubMedGoogle Scholar
  118. Pette D (2001) Historical Perspectives: plasticity of mammalian skeletal muscle. J Appl Physiol 90:1119–1124PubMedGoogle Scholar
  119. Rabinovsky ED (2004) The multifunctional role of IGF-1 in peripheral nerve regeneration. Neurol Res 26:204–210PubMedGoogle Scholar
  120. Raynaud F, Carnac G, Marcilhac A, Benyamin Y (2004) m-Calpain implication in cell cycle during muscle precursor cell activation. Exp Cell Res 298:48–57PubMedGoogle Scholar
  121. Reinstein E, Ciechanover A (2006) Narrative review: protein degradation and human diseases: the ubiquitin connection. Ann Intern Med 145:676–684PubMedGoogle Scholar
  122. Reynolds TH, Bodine SC, Lawrence JC Jr (2002) Control of Ser2448 phosphorylation in the mammalian target of rapamycin by insulin and skeletal muscle load. J Biol Chem 277:17657–17662PubMedGoogle Scholar
  123. Rodgers BD (2005) Insulin-like growth factor-I downregulates embryonic myosin heavy chain (eMyHC) in myoblast nuclei. Growth Horm IGF Res 15:377–383PubMedGoogle Scholar
  124. Rommel C, Bodine SC, Clarke BA, Rossman R, Nunez L, Stitt TN, Yancopoulos GD, Glass DJ (2001) Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol 3:1009–1013PubMedGoogle Scholar
  125. Russell B, Motlagh D, Ashley WW (2000) Form follows function: how muscle shape is regulated by work. J Appl Physiol 88:1127–1132PubMedGoogle Scholar
  126. Sakamoto K, Arnolds DE, Ekberg I, Thorell A, Goodyear LJ (2004) Exercise regulates Akt and glycogen synthase kinase-3 activities in human skeletal muscle. Biochem Biophys Res Commun 319:419–425PubMedGoogle Scholar
  127. Salem M, Levesque H, Moon TW, Rexroad CE, Yao J (2006) Anabolic effects of feeding beta2-adrenergic agonists on rainbow trout muscle proteases and proteins. Comp Biochem Physiol A Mol Integr Physiol 144:145–154PubMedGoogle Scholar
  128. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH, Goldberg AL (2004) Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117:399–412PubMedGoogle Scholar
  129. Schakman O, Thissen JP (2006) Gene therapy with anabolic growth factors to prevent muscle atrophy. Curr Opin Clin Nutr Metab Care 9:207–213PubMedGoogle Scholar
  130. Schulz RA, Yutzey KE (2004) Calcineurin signaling and NFAT activation in cardiovascular and skeletal muscle development. Dev Biol 266:1–16PubMedGoogle Scholar
  131. Schulze PC, Fang J, Kassik KA, Gannon J, Cupesi M, MacGillivray C, Lee RT, Rosenthal N (2005) Transgenic overexpression of locally acting insulin-like growth factor-1 inhibits ubiquitin-mediated muscle atrophy in chronic left-ventricular dysfunction. Circ Res 97:418–426PubMedGoogle Scholar
  132. Shavlakadze T, Grounds M (2006) Of bears, frogs, meat, mice and men: complexity of factors affecting skeletal muscle mass and fat. Bioessays 28:994–1009PubMedGoogle Scholar
  133. Shavlakadze T, Winn N, Rosenthal N, Grounds MD (2005) Reconciling data from transgenic mice that overexpress IGF-I specifically in skeletal muscle. Growth Horm IGF Res 15:4–18PubMedGoogle Scholar
  134. Sleeper MM, Kearns CF, McKeever KH (2002) Chronic clenbuterol administration negatively alters cardiac function. Med Sci Sports Exerc 34:643–650PubMedGoogle Scholar
  135. Song YH, Godard M, Li Y, Richmond SR, Rosenthal N, Delafontaine P (2005a) Insulin-like growth factor I-mediated skeletal muscle hypertrophy is characterized by increased mTOR-p70S6K signaling without increased Akt phosphorylation. J Investig Med 53:135–142Google Scholar
  136. Song YH, Li Y, Du J, Mitch WE, Rosenthal N, Delafontaine P (2005b) Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. J Clin Invest 115:451–458Google Scholar
  137. Spate U, Schulze PC (2004) Proinflammatory cytokines and skeletal muscle. Curr Opin Clin Nutr Metab Care 7:265–269PubMedGoogle Scholar
  138. Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Kline WO, Gonzalez M, Yancopoulos GD, Glass DJ (2004) The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 14:395–403PubMedGoogle Scholar
  139. Strbenc M, Smerdu V, Pogacnik A, Fazarinc G (2006) Myosin heavy chain isoform transitions in canine skeletal muscles during postnatal growth. J Anat 209:149–163PubMedGoogle Scholar
  140. Stupka N, Plant DR, Schertzer JD, Emerson TM, Bassel-Duby R, Olson EN, Lynch GS (2006) Activated calcineurin ameliorates contraction-induced injury to skeletal muscles of mdx dystrophic mice. J Physiol 575:645–656PubMedGoogle Scholar
  141. Svanberg E, Ohlsson C, Kimball SR, Lundholm K (2000) rhIGF-I/IGFBP-3 complex, but not free rhIGF-I, supports muscle protein biosynthesis in rats during semistarvation. Eur J Clin Invest 30:438–446PubMedGoogle Scholar
  142. Tajbakhsh S (2005) Skeletal muscle stem and progenitor cells: reconciling genetics and lineage. Exp Cell Res 306:364–372PubMedGoogle Scholar
  143. Tian T, Meng AM (2006) Nodal signals pattern vertebrate embryos. Cell Mol Life Sci 63:672–685PubMedGoogle Scholar
  144. Tiffin N, Adi S, Stokoe D, Wu NY, Rosenthal SM (2004) Akt phosphorylation is not sufficient for insulin-like growth factor-stimulated myogenin expression but must be accompanied by down-regulation of mitogen-activated protein kinase/extracellular signal-regulated kinase phosphorylation. Endocrinology 145:4991–4996PubMedGoogle Scholar
  145. Tisdale MJ (2005) The ubiquitin-proteasome pathway as a therapeutic target for muscle wasting. J Support Oncol 3:209–217PubMedGoogle Scholar
  146. Wagers AJ, Conboy IM (2005) Cellular and molecular signatures of muscle regeneration: current concepts and controversies in adult myogenesis. Cell 122:659–667PubMedGoogle Scholar
  147. Walsh FS, Celeste AJ (2005) Myostatin: a modulator of skeletal-muscle stem cells. Biochem Soc Trans 33:1513–1517PubMedGoogle Scholar
  148. Wehling M, Cai B, Tidball JG (2000) Modulation of myostatin expression during modified muscle use. Faseb J 14:103–110PubMedGoogle Scholar
  149. Wei W, Fareed MU, Evenson A, Menconi MJ, Yang H, Petkova V, Hasselgren PO (2005) Sepsis stimulates calpain activity in skeletal muscle by decreasing calpastatin activity but does not activate caspase-3. Am J Physiol Regul Integr Comp Physiol 288:R580–R590PubMedGoogle Scholar
  150. Wei W, Yang H, Cao P, Menconi M, Chamberlain C, Petkova V, Hasselgren PO (2006) Degradation of C/EBPbeta in cultured myotubes is calpain-dependent. J Cell Physiol 208:386–398PubMedGoogle Scholar
  151. Winn N, Paul A, Musaro A, Rosenthal N (2002) Insulin-like growth factor isoforms in skeletal muscle aging, regeneration, disease. Cold Spring Harb Symp Quant Biol 67:507–518PubMedGoogle Scholar
  152. World Anti-Doping Agency (2003) The World Anti-Doping Code, W. A.-D. A. WADAGoogle Scholar
  153. World Anti-Doping Agency (2006) The 2007 Prohibited List. International Standard, W. A.-D. A. WADAGoogle Scholar
  154. Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and metabolism. Cell 124:471–484PubMedGoogle Scholar
  155. Xu Q, Wu Z (2000) The insulin-like growth factor-phosphatidylinositol 3-kinase-Akt signaling pathway regulates myogenin expression in normal myogenic cells but not in rhabdomyosarcoma-derived RD cells. J Biol Chem 275:36750–36757PubMedGoogle Scholar
  156. Yamaoka S, Courtois G, Bessia C, Whiteside ST, Weil R, Agou F, Kirk HE, Kay RJ, Israel A (1998) Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation. Cell 93:1231–1240PubMedGoogle Scholar
  157. Yimlamai T, Dodd SL, Borst SE, Park S (2005) Clenbuterol induces muscle-specific attenuation of atrophy through effects on the ubiquitin-proteasome pathway. J Appl Physiol 99:71–80PubMedGoogle Scholar
  158. Zammit PS, Partridge TA, Yablonka-Reuveni Z (2006) The skeletal muscle satellite cell: the stem cell that came in from the cold. J Histochem Cytochem 54:1177–1191PubMedGoogle Scholar
  159. Zandi E, Rothwarf DM, Delhase M, Hayakawa M, Karin M (1997) The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell 91:243–252PubMedGoogle Scholar
  160. Zeman RJ, Peng H, Etlinger JD (2004) Clenbuterol retards loss of motor function in motor neuron degeneration mice. Exp Neurol 187:460–467PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2008

Authors and Affiliations

  • Tommaso Nastasi
    • 1
  • Nadia Rosenthal
    • 1
  1. 1.Mouse Biology Unit, European Molecular Biology Laboratory00015 Monterotondo Scalo (Rome)Italy

Personalised recommendations